It seems like the S&P 500 is on an upward trend, with experts like Savita Subramanian from Bank of America predicting continued momentum. Subramanian emphasizes the importance of long-term shareholding and advises against trying to time the market.
Bank of America analysts are recommending two stocks with significant upside potential: Sutro Biopharma (STRO) and Avidity Biosciences (RNA). Both companies are in the biotech sector and have promising drug candidates in their pipelines.
Sutro Biopharma’s leading drug candidate, luvelta, has shown promise in treating ovarian cancer, while Avidity Biosciences is focused on developing targeted RNA therapeutic agents for rare muscle diseases. Both companies have proprietary technology platforms that set them apart in their respective fields.
Analysts are bullish on both STRO and RNA, with strong buy ratings and price targets indicating significant upside potential. Investors looking for opportunities in the biotech sector may want to consider these two stocks for their portfolios.